{"commentary":{"count":216,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":131,"youtube":48,"podcast":34,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03907488\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03907488","nct_id":"NCT03907488","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03907488. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.","label":"Arm I (chemotherapy, nivolumab, radiation)","type":"EXPERIMENTAL"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.","label":"Arm II (chemotherapy, brentuximab vedotin, radiation)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-28","type":"ESTIMATED"},"conditions":["Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma","Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma","Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma","Classic Hodgkin Lymphoma","Lymphocyte-Rich Classic Hodgkin Lymphoma"],"enrollment":{"count":994,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Brentuximab Vedotin","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Dacarbazine","type":"DRUG"},{"name":"Doxorubicin Hydrochloride","type":"DRUG"},{"name":"Filgrastim","type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Pegfilgrastim","type":"BIOLOGICAL"},{"name":"Positron Emission Tomography","type":"PROCEDURE"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"},{"name":"Radiation Therapy","type":"RADIATION"},{"name":"Vinblastine Sulfate","type":"DRUG"}],"last_update":"2026-10-01","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-03-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From date of registration to date of first observation of progressive disease, or death due to any cause, assessed at 2 years"}],"references":[{"citation":"Goyal G, Lurain K, Lopez G, Rutherford SC, Castellino S, Davison K, Evens A, Smith SM, Kelly K, LeBlanc M, Song JY, Odeny T, Ratner L, Friedberg JW, Herrera AF. Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma. JCO Oncol Adv. 2026 Jan;3(1):e2500143. doi: 10.1200/oa-25-00143. Epub 2026 Feb 26.","pmid":"42577949","type":"DERIVED"},{"citation":"Ahmed S, Li H, Herrera AF, Perry AM, Kovach AE, Rutherford SC, Davison K, Castellino SM, Evens AM, Kahl BS, Bartlett N, Leonard JP, Shipp MA, Smith SM, Kelly KM, LeBlanc ML, Friedberg JW, Song JYY. Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Blood Adv. 2026 Jul 29:bloodadvances.2026021402. doi: 10.1182/bloodadvances.2026021402. Online ahead of print.","pmid":"42526889","type":"DERIVED"},{"citation":"Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, Punnett A, Hodgson D, Keller FG, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Hoppe BS, Song JY, Smith SM, Friedberg JW, Kelly KM. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. J Clin Oncol. 2026 Feb 20;44(6):449-454. doi: 10.1200/JCO-25-00203. Epub 2026 Jan 9.","pmid":"41512237","type":"DERIVED"},{"citation":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888.","pmid":"39413375","type":"DERIVED"},{"citation":"McKenna M, Ryu Tiger YK, Rutherford SC, Evens AM. The Management of older patients with Hodgkin lymphoma: implications of S1826. Semin Hematol. 2024 Aug;61(4):236-244. doi: 10.1053/j.seminhematol.2024.05.004. Epub 2024 Jun 4.","pmid":"38945791","type":"DERIVED"},{"citation":"Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.","pmid":"37505794","type":"DERIVED"}],"start_date":{"date":"2019-08-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT03907488"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03907488"}